OTCPK:RVVQ.F

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

RavenQuest BioMed Inc., a cannabis company, focuses on the cannabis production, management services and consulting, and specialized research and development activities.


Snowflake Analysis

Overvalued with worrying balance sheet.

Share Price & News

How has RavenQuest BioMed's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: RVVQ.F's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-19.0%

RVVQ.F

4.0%

US Professional Services

4.0%

US Market


1 Year Return

-96.1%

RVVQ.F

10.9%

US Professional Services

4.9%

US Market

Return vs Industry: RVVQ.F underperformed the US Professional Services industry which returned 10.9% over the past year.

Return vs Market: RVVQ.F underperformed the US Market which returned 5% over the past year.


Shareholder returns

RVVQ.FIndustryMarket
7 Day-19.0%4.0%4.0%
30 Day177.2%2.6%1.3%
90 Day216.0%32.5%29.5%
1 Year-96.1%-96.1%11.7%10.9%7.2%4.9%
3 Yearn/a50.9%46.4%36.1%27.2%
5 Yearn/a79.0%69.9%65.3%46.9%

Price Volatility Vs. Market

How volatile is RavenQuest BioMed's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is RavenQuest BioMed undervalued compared to its fair value and its price relative to the market?

0.03x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate RVVQ.F's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate RVVQ.F's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: RVVQ.F is unprofitable, so we can't compare its PE Ratio to the Professional Services industry average.

PE vs Market: RVVQ.F is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate RVVQ.F's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: RVVQ.F is good value based on its PB Ratio (0x) compared to the US Professional Services industry average (2.8x).


Next Steps

Future Growth

How is RavenQuest BioMed forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.4%

Forecasted Commercial Services industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as RavenQuest BioMed has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of RVVQ.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access RavenQuest BioMed's filings and announcements here.
  • Explore growth companies in the Commercial Services industry.

Past Performance

How has RavenQuest BioMed performed over the past 5 years?

-85.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: RVVQ.F is currently unprofitable.

Growing Profit Margin: RVVQ.F is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: RVVQ.F is unprofitable, and losses have increased over the past 5 years at a rate of -85% per year.

Accelerating Growth: Unable to compare RVVQ.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RVVQ.F is unprofitable, making it difficult to compare its past year earnings growth to the Professional Services industry (9.5%).


Return on Equity

High ROE: RVVQ.F has a negative Return on Equity (-157.56%), as it is currently unprofitable.


Next Steps

Financial Health

How is RavenQuest BioMed's financial position?


Financial Position Analysis

Short Term Liabilities: RVVQ.F's short term assets (CA$2.8M) do not cover its short term liabilities (CA$5.6M).

Long Term Liabilities: RVVQ.F's short term assets (CA$2.8M) do not cover its long term liabilities (CA$13.3M).


Debt to Equity History and Analysis

Debt Level: RVVQ.F's debt to equity ratio (72%) is considered high.

Reducing Debt: RVVQ.F had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if RVVQ.F has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if RVVQ.F has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is RavenQuest BioMed current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate RVVQ.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate RVVQ.F's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if RVVQ.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RVVQ.F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of RVVQ.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.7yrs

Average management tenure


CEO

W. Robinson

2.83yrs

Tenure

CA$240,000

Compensation

Mr. W. George Robinson has been Chief Executive Officer and Director of Ravenquest Biomed Inc. since September 7, 2017 and serves as its President. 


CEO Compensation Analysis

Compensation vs Market: W.'s total compensation ($USD0.00) is below average for companies of similar size in the US market ($USD605.69K).

Compensation vs Earnings: W.'s compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
W. Robinson
CEO, President & Director2.83yrsCA$240.00k3.61% CA$24.2k
David Cross
Chief Financial Officer2.83yrsCA$80.20kno data
Mathieu Mcdonald
Head of Corporate Communications0.50yrno datano data
Andy Schinke
Head of Sales & Product Acquisition0.50yrno datano data
Shayne Taker
Head of Orbital Garden Mfg & Procurement0.50yrno datano data
Marla Ritchie
Corporate Secretary2.83yrsno datano data

1.7yrs

Average Tenure

Experienced Management: RVVQ.F's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
W. Robinson
CEO, President & Director2.83yrsCA$240.00k3.61% CA$24.2k
Anton Drescher
Director2.83yrsCA$120.00kno data
Hendrik Van Alphen
Director2.83yrsno datano data
Christopher Bechtel
Director2.83yrsno data0.99% CA$6.6k
Jorge Bonet
Director2.83yrsno datano data

2.8yrs

Average Tenure

63yo

Average Age

Experienced Board: RVVQ.F's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 49.7%.


Top Shareholders

Company Information

RavenQuest BioMed Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: RavenQuest BioMed Inc.
  • Ticker: RVVQ.F
  • Exchange: OTCPK
  • Founded: 1987
  • Industry: Research and Consulting Services
  • Sector: Commercial Services
  • Market Cap: CA$910.653k
  • Listing Market Cap: CA$670.920k
  • Shares outstanding: 182.13m
  • Website: https://www.rqbglobal.com

Location

  • RavenQuest BioMed Inc.
  • 580 Hornby Street
  • Suite 780
  • Vancouver
  • British Columbia
  • V6E 2K3
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
RQBCNSX (Canadian National Stock Exchange)YesCommon SharesCACADOct 2012
1ITDB (Deutsche Boerse AG)YesCommon SharesDEEUROct 2012
RVVQ.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDOct 2012

Biography

RavenQuest BioMed Inc., a cannabis company, focuses on the cannabis production, management services and consulting, and specialized research and development activities. The company operates in two segments, Consulting Business, and Cultivation and Sale of Medical Cannabis. It offers its products under the Lore Cannabis and Bloomera brand names. The company was formerly known as Ravencrest Resources Inc. and changed its name to RavenQuest BioMed Inc. in September 2017. RavenQuest BioMed Inc. was incorporated in 1987 and is based in Vancouver, Canada. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/05 00:38
End of Day Share Price2020/07/02 00:00
Earnings2019/07/31
Annual Earnings2018/10/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.